Suchergebnisse - (Person:"Gökmen-Polar, Yesim")

PubPharm (112)

21

Independent Validation of EarlyR Gene Signature in BIG 1-98 : A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer

enthalten in: JNCI cancer spectrum | 2019

von Buechler, S. | Gray, K. | Gökmen-Polar, Y. | +7

22

TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer : Company Matters

enthalten in: Journal of the National Cancer Institute | 2019

von Badve, S. | Gökmen-Polar, Y.

CommentOn: J Natl Cancer Inst. 2019 Nov 1;111(11):1202-1215. - PMID 30990221

23

Ductal carcinoma in situ of breast : update 2019

enthalten in: Pathology | 2019

von Badve, S. | Gökmen-Polar, Y.

24

Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues

enthalten in: Scientific reports | 2019

von Chen, Y. | Shen, Q. | White, S. | +3

25

EarlyR : A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer

enthalten in: Clinical breast cancer | 2019

von Buechler, S. | Gökmen-Polar, Y. | Badve, S.

26

Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways

enthalten in: EMBO reports | 2019

von Gökmen-Polar, Y. | Neelamraju, Y. | Goswami, C. | +7

27

EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer

enthalten in: Breast (Edinburgh, Scotland) | 2019

von Buechler, S. | Gökmen-Polar, Y. | Badve, S.

28

HSF1 as a Cancer Biomarker and Therapeutic Target

enthalten in: Current cancer drug targets | 2019

von Carpenter, R. | Gökmen-Polar, Y.

29

HSF1 as a Cancer Biomarker and Therapeutic Target

enthalten in: Current cancer drug targets | 2019

von Carpenter, R. | Gokmen-Polar, Y.

30

Splicing factor ESRP1 controls ER‐positive breast cancer by altering metabolic pathways

enthalten in: EMBO reports | 2019

von Gökmen‐Polar, Y. | Neelamraju, Y. | Goswami, C. | +7